(585) Impact of the SarsCov2 Booster Dose on Clinical Events in Heart Transplant Patients in Galicia. INMU TC Study

our single center experience of heart transplant recipients infected with COVID-19 in whom IS was maintained.Methods: Retrospective analysis from June 2020 to February 2022 of heart transplant recipients followed at our center that tested positive for COVID-19.Patient demographics, comorbidities, baseline IS, hospitalization, ICU need, O2 requirement, mechanical support requirement and mortality were recorded.Results: During the study period, 581 transplants were followed at our center, we documented 65 cases of COVID-19 (Table 1).The average age was 58 years, 75% male, 51% Caucasian.50% had DM, 69% HTN and 48% CKD.Median time since OHT was 4.6 years.71% of the patients were on dual IS.All patients remained on their baseline immunosuppression.Of the 65 patients, 37% required hospitalization, 9% ICU-level of care.Median LOS was 5.5 days.Mortality was 8%, there were no events of rejection or allograph dysfunction.Conclusion: Our data suggest that maintenance of therapeutical levels of IS in patients with COVID-19 is safe in heart transplant recipients.Our outcomes were comparable to those of the existing literature.Larger studies are needed to further validate our results.